About
23andMe’s chief scientific officer and former therapeutics foreman Richard Scheller has left his hands-on role at the sequencing company and landed on the boards of at least two biotechs—namely, two of the biggest money raisers of the year so far. At BridgeBio, which recently went public and brought in nearly $350 million with its IPO, Scheller now holds the title of chairman of R&D, a vaguely defined and apparently part-time position. Meanwhile, the genetics-focused Maze Therapeutics has also claimed him for a seat on its board of directors, following its February premiere with a $191 million series A round. Scheller will continue on as a board member of 23andMe, as well.
Investment Focus
- Location
- San Francisco, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Richard
Search Investors